康护乐小编告诉你注射用硫酸多黏菌素B的作用功效

Efficacy: Polymyxin B sulfate for injection is clinically used to fight infections caused by Gram-negative bacilli, mainly Pseudomonas aeruginosa. Including urinary tract infections, meningitis, lung infections, sepsis, and skin, soft tissue, eye, ear, joint infections, etc. It also has a good therapeutic effect on infections caused by other negative bacteria such as Aerobacillus aerogenes, Escherichia coli, Pneumoniae bacilli, and influenzae bacilli. There is no complete cross-resistance between bacteria and polymyxin E.

To study and analyze the clinical use of polymyxin B sulfate for injection, to provide reference for standardizing its clinical use and improving control measures. The researchers summarized the information of inpatients who used polymyxin B sulfate for injection in the hospital from January 1, 2018 to August 31, 2019, and analyzed the patient population characteristics, medication indications, usage and dosage, medication duration, combined medication and etiological examination results, clinical treatment outcomes and adverse reactions, etc.

As a result, a total of 63 hospitalized patients using polymyxin B sulfate for injection were collected, including 40 male patients (64.06%) and 23 female patients (35.93%). The average age was (61.12±15.25) years old and the average length of stay was (66.54±56.98) days. Mainly distributed in 15 departments including the Respiratory Intensive Care Unit, Critical Care Medicine Department and Hematology Department. The top three infection categories were pulmonary infection (49 cases, 51.58%), bloodstream infection (23 cases, 24.21%) and abdominal infection (16 cases, 16.84%). All 63 patients had etiological examinations, and the examination submission rate was 100%. In the end, 0 patients were cured, 5 were markedly effective, 11 were improved, 16 were ineffective, and 23 died. 8 patients could not be judged because the medication time was ≤48 hours. A total of 17 patients (26.98%) developed acute kidney injury (AKI). According to the AKI staging, 10 patients were in AKI stage 1, 4 were in AKI stage 2, and 3 patients in stage 3 AKI underwent continuous renal replacement therapy (CRRT).

Conclusion: All patients using polymyxin B sulfate for injection in our hospital have clear indications; the renal toxicity of polymyxin B sulfate for injection should not be underestimated and should be paid attention to in clinical use.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: